Stock SAVA CASSAVA SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Real-time Estimate Cboe BZX
Other stock markets
 13:16:35 2024-05-03 EDT 		5-day change 1st Jan Change
22.26 USD +0.91% Intraday chart for Cassava Sciences, Inc. +0.04% -0.71%
04-29 North American Morning Briefing : Investors Brace -2- DJ
03-25 Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
B. Riley Cuts Cassava Sciences' PT to $28 From $44 on 'Uninterpretable' Open-Label Results of Simuflam in Alzheimer's Disease Patients; Keeps Neutral Rating
MT
B. Riley Downgrades Cassava Sciences to Neutral From Buy, Notes Challenging Near-Term Catalyst Profile, Prolonged Litigation Mess; Maintains $44 PT
MT
B. Riley Securities Lowers Cassava Sciences' Price Target to $44 from $58, Retains Buy Rating
MT
B. Riley Lowers Cassava Sciences' Price Target to $58 from $72 to Factor in Increased Pace of Research & Development Expenses; Keeps Buy Rating
MT
Univest Securities Starts Cassava Sciences at Sell With $8 Price Target, Says Phase 3 Trials Unlikely to Lead to Commercialization, Expects Further Stock Dilution
MT
Maxim Group Adjusts Cassava Sciences Price Target to $110 From $190, Maintains Buy Rating
MT
B. Riley Lowers Cassava Sciences' Price Target to $72 from $108 After Revising Cost Capital Assumptions, Keeps Buy Rating
MT
CASSAVA SCIENCES : B. Riley Lowers Cassava Sciences' PT to $108 from $145 on Investor Concerns Over Alleged Scientific Misconduct; Keeps Buy Rating
MT
CASSAVA SCIENCES : B. Riley Raises Cassava Sciences' PT to $145 from $111 After Management Q&A on Simufilam, Keeps Buy Rating
MT
CASSAVA SCIENCES : HC Wainwright Adjusts Cassava Sciences' Price Target to $124 From $97, Keeps Buy Rating
MT
CASSAVA SCIENCES : Cantor Fitzgerald Downgrades Cassava Sciences to Neutral From Overweight, Adjusts PT to $100 From $73
MT
CASSAVA SCIENCES : B. Riley Raises Cassava Sciences' PT to $111 from $78 on Regulatory Tailwinds for Late-Stage AD Therapeutic, Keeps Buy Rating
MT
CASSAVA SCIENCES : B. Riley Starts Cassava Sciences at Buy With $78 Price Target
MT
CASSAVA SCIENCES : JonesTrading Initiates Cassava Sciences at Buy with $110 Price Target
MT
CASSAVA SCIENCES : HC Wainwright & Co. Adjusts Price Target on Cassava Sciences, Inc to $97 From $66, Maintains Buy Rating
MT
CASSAVA SCIENCES : Maxim Raises Cassava Sciences' Price Target to Street-High $80 from $14, Keeps Buy Rating
MT
CASSAVA SCIENCES : HC Wainwright Adjusts Cassava Sciences' Price Target to $66 From $20, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAVA Stock
  4. News Cassava Sciences, Inc.
  5. Analyst Reco.